Ki-67 Expression in Urinary Bladder Carcinomas and Its Prognostic Role
Keywords:
Ki-67, Transitional Cell Carcinoma, Bladder Carcinoma, Immunohistochemisrty, Cell Proliferation Markers
Abstract
Background: Transitional cell carcinoma is the commonest histological type of bladder malignancies.There is a need for good prognostic markers that help to decide which group of patients need to be subjected to chemotherapy.The present study determines the expression of the cell proliferative marker Ki-67 and correlates it with pathologic features and disease prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.Methods: Immunohistochemical staining for Ki-67 was done on tissue blocks ofcystectomy specimens from patients with bladder TCC.Results: Ki-67 expression was increased in 56% of cystectomy specimens. Ki-67 overexpression was associated with advanced pathologic stage, higher grade, and metastases to lymph nodes (P = 0.001, 0.040., and 0.036, respectively).Conclusion: Ki-67 overexpression is associated with features of aggressive bladder TCC and adds independent prognostic information to standard pathologic features for prediction of clinical outcome after radical cystectomy.References
1. Cookson MS. The surgical management of muscle invasive bladder cancer: a contemporary review. SeminRadiatOncol 2005;15:10–8.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cys-tectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J ClinOncol 2001;19:666–75.
3. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357–63.
4. Li R, Heydon K, Hammond ME, et al. Ki-67 stain-ing index predicts distant metastasis and survival in locally advanced prostate cancer treated with radio-therapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004;10:4118–24.
5. Morinaga S, Ishiwa N, Noguchi Y, et al. Growth index, assessed with Ki-67 and ssDNA labeling; a significant prognosticator for patients undergoing curative resection for hepatocellular carcinoma. J SurgOncol 2005;92:331–6.
6. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expres-sion, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J ClinOncol 2005;23: 8048–56.
7. Lebret T, Becette V, Herve JM, et al. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. EurUrol 2000;37:654–9.
8. Pich A, Chiusa L, Formiconi A, et al. Proliferative activity is the most significant predictor of recur-rence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002;95:784–90.
9. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the blad-der. J ClinPathol 2006;59:83–8.
10. Su JS, Arima K, Hasegawa M, et al. Proliferative status is a risk index for recurrence in primary su-perficial (pTa/T1) low-grade urothelial bladder car-cinoma. Hinyokika Kiyo 2003;49:649–58.
11. Popov Z, Hoznek A, Colombel M, et al. The prog-nostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472–81.
12. Suwa Y, Takano Y, Iki M, Asakura T, Noguchi S, Masuda M. Prognostic significance of Ki-67 ex-pression in transitional cell bladder carcinoma after radical cystectomy. Pathol Res Pract 1997;193:551–6.
13. Brown DC, Gatter KC. Ki67 protein: the immacu-late deception? Histopathology 2002;40:2–11.
14. Frank I, Cheville JC, Blute ML, et al. Prognostic value of p53 and MIB-1 in transitional cell carci-noma of the urinary bladder with regional lymph node involvement. Cancer 2004;101:1803–8.
15. Habuchi T, Marberger M, Droller MJ, et al. Prog-nostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urolo-gy 2005;66:64–74.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cys-tectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J ClinOncol 2001;19:666–75.
3. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357–63.
4. Li R, Heydon K, Hammond ME, et al. Ki-67 stain-ing index predicts distant metastasis and survival in locally advanced prostate cancer treated with radio-therapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004;10:4118–24.
5. Morinaga S, Ishiwa N, Noguchi Y, et al. Growth index, assessed with Ki-67 and ssDNA labeling; a significant prognosticator for patients undergoing curative resection for hepatocellular carcinoma. J SurgOncol 2005;92:331–6.
6. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expres-sion, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J ClinOncol 2005;23: 8048–56.
7. Lebret T, Becette V, Herve JM, et al. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. EurUrol 2000;37:654–9.
8. Pich A, Chiusa L, Formiconi A, et al. Proliferative activity is the most significant predictor of recur-rence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002;95:784–90.
9. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the blad-der. J ClinPathol 2006;59:83–8.
10. Su JS, Arima K, Hasegawa M, et al. Proliferative status is a risk index for recurrence in primary su-perficial (pTa/T1) low-grade urothelial bladder car-cinoma. Hinyokika Kiyo 2003;49:649–58.
11. Popov Z, Hoznek A, Colombel M, et al. The prog-nostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472–81.
12. Suwa Y, Takano Y, Iki M, Asakura T, Noguchi S, Masuda M. Prognostic significance of Ki-67 ex-pression in transitional cell bladder carcinoma after radical cystectomy. Pathol Res Pract 1997;193:551–6.
13. Brown DC, Gatter KC. Ki67 protein: the immacu-late deception? Histopathology 2002;40:2–11.
14. Frank I, Cheville JC, Blute ML, et al. Prognostic value of p53 and MIB-1 in transitional cell carci-noma of the urinary bladder with regional lymph node involvement. Cancer 2004;101:1803–8.
15. Habuchi T, Marberger M, Droller MJ, et al. Prog-nostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urolo-gy 2005;66:64–74.
Published
2015-12-18
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
